Skip to content
Subscriber Only
Business
Prognosis

Pfizer, BioNTech to Supply Up to 40 Million Shots to Covax

  • Vaccine to be offered on a not-for-profit basis, Pfizer says
  • Covax alliance aims to boost immunization around the world
Tucson Medical Center Administers Covid-19 Vaccinations To Group 1B
Photographer: Cheney Orr/Bloomberg
Updated on

Pfizer Inc. and BioNTech SE will supply as many as 40 million doses of their Covid-19 vaccine to Covax, a global alliance many poorer countries are relying on to protect their populations.

Shipments will start in the first quarter and continue throughout 2021, the companies said in a statement. The agreement follows pacts with AstraZeneca Plc, whose shot is approved in the U.K., and other drugmakers such as Johnson & Johnson that are working on potential vaccines.